Company research
ENDRA Life Sciences Inc.
CIK 1681682Updated Sep 27, 2026
SecurityNDRA · NASDAQ · equity
Historical securities (1)
NDRAW · NASDAQ · warrant · closed May 13, 2022Name history
Endra Inc. · through Sep 21, 2016
NDRA price & chart
Loading TradingView…
NASDAQ:NDRA on TradingView ↗About the company
Inc. ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
Endra Life Sciences GAAP EPS of -$1.09 ↗
Endra Life Sciences GAAP EPS of -$8.93 misses by $2.34 ↗
SEC disclosures
ENDRA Life Sciences Inc. files merger communication (425) ↗
Recent filings
425 filing
425 filing
425 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
425 filing
Other Events
Items 8.01
425 filing
Entry into a Material Definitive Agreement · Changes in Control of Registrant · Regulation FD Disclosure · Other Events
Items 1.01, 5.01, 7.01, 8.01, 9.01
425 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,853,797Source | 4,452,362Source | 6,754,146Source | 9,274,147Source |
| Property, Plant and Equipment, NetUSD | 42,516Source | 69,281Source | 111,782Source | 235,655Source |
| Current assets: | ||||
| Inventory, NetUSD | 0Source | 0Source | 2,622,865Source | 2,644,717Source |
| Assets, CurrentUSD | 967,969Source | 3,433,665Source | 3,032,812Source | 8,526,690Source |
| Operating Lease, Right-of-Use AssetUSD | 461,949Source | 578,013Source | 354,091Source | 505,816Source |
| Other Assets, NoncurrentUSD | 5,986Source | — | — | 5,986Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,593,677Source | 1,891,996Source | 1,095,157Source | 2,069,643Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 116Source | 53Source | 1,039Source | 317Source |
| Additional Paid in CapitalUSD | 112,725,513Source | 105,998,412Source | 97,582,868Source | 89,068,015Source |
| Retained Earnings (Accumulated Deficit)USD | -110,465,509Source | -103,438,099Source | -91,930,152Source | -81,869,902Source |
| Stockholders' Equity Attributable to ParentUSD | 2,260,120Source | 2,560,366Source | 5,658,989Source | 7,204,504Source |
| Liabilities and EquityUSD | 3,853,797Source | 4,452,362Source | 6,754,146Source | 9,274,147Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 750,956Source | 605,230Source | 903,095Source | 1,703,724Source |
| Operating Lease, Liability, CurrentUSD | 129,378Source | 96,937Source | 173,857Source | 152,228Source |
| Accounts Payable, CurrentUSD | 382,970Source | 269,683Source | 360,401Source | 613,961Source |
| Operating Lease, Liability, NoncurrentUSD | 362,974Source | 487,482Source | 192,062Source | 365,919Source |
| Additional Financial Items | ||||
| Long-term DebtUSD | — | 0Source | 0Source | 365,919Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -11,507,947Source | — | 13,179,092Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 44,045Source | 46,489Source | — | 96,661Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 329,409Source | 571,924Source | 996,430Source | 1,199,838Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | — | -235,731Source | 116,193Source | 1,360,139Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,182,558Source | -7,400,547Source | -9,548,775Source | -12,769,371Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -3,017,280Source | -12,796Source | -24,721Source | -202,577Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 17,280Source | 16,000Source | 33,884Source | 202,577Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 5,732,723Source | 7,808,917Source | 7,518,305Source | 8,399,512Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 762,365Source | 3,229,480Source | 2,833,907Source | 4,889,098Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 55,848Source | 31,910Source | 44,985Source | 59,113Source |
| Income Taxes Paid, NetUSD | — | 0Source | 0Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 186,287Source | — | — | — |
| DepreciationUSD | 44,045Source | 46,489Source | 123,726Source | 96,661Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 3,723,635Source | 7,055,814Source | 4,696,486Source | 5,174,215Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -7,027,410Source | -11,507,947Source | -10,060,250Source | -13,179,092Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -13,179,092Source |
| Nonoperating Income (Expense)USD | -1,264,309Source | — | 460,485Source | -21,533Source |
| Operating ExpensesUSD | 5,763,101Source | 10,817,147Source | 10,520,735Source | 13,157,559Source |
| Other Nonoperating Income (Expense)USD | — | -690,800Source | 460,485Source | -21,533Source |
| Proceeds from Issuance of Common StockUSD | 1,218,241Source | 1,148,470Source | 6,483,393Source | 8,399,512Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -5,763,101Source | -10,817,147Source | -10,520,735Source | -13,157,559Source |
| Other Nonoperating Income (Expense)USD | — | -690,800Source | 460,485Source | -21,533Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -7,027,410Source | -11,507,947Source | -10,060,250Source | -13,179,092Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -7,027,410Source | -11,507,947Source | -10,060,250Source | -13,179,092Source |
| Earnings Per Share, BasicUSD per share | -8.93Source | — | — | -4.56Source |
| Earnings Per Share, DilutedUSD per share | -8.93Source | -56.94Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 787,020Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 787,020Source | 202,106Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 0Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 46,489Source | 123,726Source | — |
| General and Administrative ExpenseUSD | 3,723,635Source | 7,055,814Source | 4,696,486Source | 5,174,215Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -6,465,510Source | -10,434,147Source | -8,403,400Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -13,179,092Source |
| Nonoperating Income (Expense)USD | -1,264,309Source | — | 460,485Source | -21,533Source |
| Operating ExpensesUSD | 5,763,101Source | 10,817,147Source | 10,520,735Source | 13,157,559Source |
| Other IncomeUSD | 71,224Source | 108,484Source | — | — |
| Research and Development ExpenseUSD | 1,849,996Source | 3,190,293Source | 5,003,695Source | 6,554,194Source |
| Selling and Marketing ExpenseUSD | 189,470Source | 571,040Source | 820,554Source | 1,429,150Source |
Filing attachments
ea030215601ex99-1.htm · 425 · 2026-08-17
EX-99.1 2 ea030215601ex99-1.htm PRESS RELEASE DATED AUGUST 17, 2026, FURNISHED HEREWITH Exhibit 99.1 August 17, 2026 ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update ANN ARBOR, Mich., (BUSINESS WIRE) - ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 20…
Read attachment ↗ea030215601ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 ea030215601ex99-1.htm PRESS RELEASE DATED AUGUST 17, 2026, FURNISHED HEREWITH Exhibit 99.1 August 17, 2026 ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update ANN ARBOR, Mich., (BUSINESS WIRE) - ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 20…
Read attachment ↗ea029523901ex99-1.htm · 8-K · 2026-06-26
EX-99.1 5 ea029523901ex99-1.htm RENERGEN INVESTOR PRESENTATION Exhibit 99.1 Investor Presentation June 2026 CONFIDENTIAL | NOT FOR FURTHER DISTRIBUTION CONFIDENTIAL | NOT FOR FURTHER DISTRIBUTION Disclaimers 1 This presentation (including any accompanying oral presentation, this “Presentation”) is being furnished solely to recipients that are “qualified institutional buyers” (as defined in Rule 144 A of the Securities Act of 1933, as amended (the “Securities Act”)), “accredited investors” …
Read attachment ↗ea029589901ex99-1.htm · 8-K · 2026-06-25
EX-99.1 2 ea029589901ex99-1.htm PRESS RELEASE DATED JUNE 25, 2026 Exhibit 99.1 ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing Combination, if successful, would establish Noble Africa as a Nasdaq-listed helium platform for Renergen’s Virginia Gas Project Listing expected to provide investors with direct exposure to one of the few publicly traded helium development assets globally, at a tim…
Read attachment ↗ea029221601ex4-1.htm · 8-K · 2026-05-28
EX-4.1 2 ea029221601ex4-1.htm FORM OF COMMON WARRANT Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT O…
Read attachment ↗ea029221601ex4-2.htm · 8-K · 2026-05-28
EX-4.2 3 ea029221601ex4-2.htm FORM OF PREFUNDED WARRANT Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC…
Read attachment ↗